← ORGANIGRAM GLOBAL INC.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Net loss | ($9.5m) | ($136.2m) | ($130.7m) | ($14.3m) | ($248.6m) | ($45.4m) | ($24.8m) | — | |
| Depreciation and amortization (Note 8 and 9) | $8.9m | $18.0m | $31.0m | $24.9m | $26.2m | $12.1m | $18.0m | $19.8m | |
| Share-based compensation (Note 14 (iv)) | $14.9m | $7.8m | $3.9m | $5.1m | $5.7m | $7.2m | $4.2m | $3.5m | |
| Net change in accounts and other receivables, biological assets, inventories, prepaid expenses and deposits | — | — | — | ($37.7m) | $13.6m | ($12.1m) | ($15.3m) | — | |
| Realized fair value on inventories sold and other inventory charges (Note 7) | — | — | $35.7m | $35.2m | $56.2m | $52.1m | $67.1m | — | |
| Net change in accounts payable and accrued liabilities, provisions and other liabilities | — | — | — | $14.8m | ($19.1m) | $27.0m | $13.2m | — | |
| Cash used in operating activities before working capital changes | ($35.1m) | ($45.1m) | ($28.6m) | ($13.3m) | ($33.3m) | ($11.1m) | ($5.5m) | ($9.6m) | |
| Net cash (used in) provided by operating activities | ($35.1m) |
($45.1m)
-28.63%
|
($28.6m)
+36.64%
|
($36.2m)
-26.66%
|
($38.8m)
-7.09%
|
$3.9m
+109.99%
|
($7.6m)
-296.05%
|
($9.6m)
-26.45%
|
|
| Loss (gain) on disposal of property, plant and equipment and intangible assets | $168k | $778k | $34k | $6.6m | $418k | ($633k) | $9k | — | |
| Proceeds on sale of property, plant and equipment | $168k | $0 | $34k | $0 | $1.0m | $257k | $112k | — | |
| Purchase of property, plant and equipment (Note 8) | ($108.8m) | ($77.2m) | ($11.8m) | ($48.7m) | ($29.1m) | ($4.7m) | ($17.0m) | — | |
| Share of loss from investments in associates (Note 16) | $1.3m | $1.2m | $1.1m | $1.4m | $1.0m | $5.3m | $0 | — | |
| Purchase of short-term investments | — | ($50.0m) | ($120.0m) | ($15.0m) | ($10.0m) | ($800k) | ($800k) | — | |
| Proceeds from short-term investments | $75.0m | $135k | $50.1m | $113.1m | $40.5m | $0 | $897k | — | |
| Net cash used in investing activities | ($46.8m) | ($138.2m) | ($115.1m) | $44.0m | $4.9m | ($38.8m) | ($81.1m) | ($15.0m) | |
| Bad debts and provision for expected credit losses (Note 5) | — | — | — | — | $0 | $4.2m | $274k | — | |
| Payment of long-term debt | ($12.7m) | ($55k) | ($115.1m) | ($82k) | ($87k) | ($76k) | ($60k) | — | |
| Net cash provided by financing activities | $74.3m |
$160.4m
+115.75%
|
$174.5m
+8.79%
|
$5.3m
-96.95%
|
($817k)
-115.33%
|
$107.8m
+13292.04%
|
$39.3m
-63.51%
|
($2.0m)
-105.15%
|
|
| (DECREASE) INCREASE IN CASH | ($7.5m) | ($23.0m) | $30.8m | $13.2m | ($34.7m) | $72.9m | ($49.0m) | ||
| Less: restricted cash | — | — | — | — | — | ($25.9m) | ($55.4m) | — | |
| Additional Supplementary Disclosures | |||||||||
| Additional Supplementary Disclosures | |||||||||
| Unrealized gain on changes in fair value of biological assets (Note 6) | ($8.1m) | ($2.9m) | ($5.7m) | ($40.0m) | ($69.0m) | ($51.2m) | ($73.0m) | — | |
| Investment income, net of financing costs | ($662k) | ($308k) | ($854k) | ($1.5m) | ($4.0m) | ($3.3m) | ($1.1m) | — | |
| Change in fair value of contingent consideration (Note 26) | $145k | ($886k) | $3.6m | ($2.6m) | ($3.4m) | ($50k) | ($9.7m) | — | |
| Change in fair value of derivative liabilities, preferred shares and other financial assets (Note 11, 12 and 13) | — | — | — | — | ($4.4m) | $7.7m | $27.5m | — | |
| Share issuance costs allocated to derivative liabilities and preferred shares (Note 14) | — | — | — | — | $0 | $937k | $170k | — | |
| Unrealized foreign exchange gain | — | — | — | — | — | $0 | ($313k) | — | |
| Income tax recovery (Note 24) | $3.6m | ($10.5m) | $0 | ($88k) | ($3.8m) | $0 | ($13.8m) | — | |
| Proceeds from unit financing, net of issuance costs (Note 14 (iii)) | — | — | — | — | $0 | $26.0m | $0 | — | |
| Private placement, net of share issuance costs (Note 14 (iii)) | — | — | — | — | $0 | $82.5m | $41.2m | — | |
| Payment of lease liabilities, net of sublease receipts (Note 15) | — | ($897k) | ($1.3m) | ($931k) | ($750k) | ($710k) | ($1.8m) | — | |
| Stock options exercised (Note 14 (iii)) | — | — | — | $6.4m | $39k | $6k | $4k | — | |
| Investment income | $1.6m | $393k | $782k | $1.5m | $3.6m | $3.5m | $1.6m | — | |
| Acquisition of subsidiary (Note 26) | — | — | $0 | ($8.4m) | $0 | $0 | ($65.6m) | — | |
| Other financial assets (Note 11) | — | — | — | $0 | ($8.6m) | ($28.4m) | ($207k) | — | |
| Purchase of intangible assets (Note 9) | ($1.5m) | ($1.4m) | ($538k) | ($30k) | ($1.3m) | ($607k) | ($27k) | — | |
| Effect of foreign exchange on cash | $26k | — | — | — | — | $0 | $313k | — | |
| Beginning of period | — | — | — | — | — | $132.6m | $83.6m | — | |
| Cash | $47.6m | $24.6m | $55.4m | $68.5m | $33.9m | $106.7m | $28.2m | ($9.6m) |